<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313792</url>
  </required_header>
  <id_info>
    <org_study_id>CBMTC-supp002</org_study_id>
    <nct_id>NCT02313792</nct_id>
  </id_info>
  <brief_title>Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BLNH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of palifermin on reducing
      mucositis for patients receiving autologous or allogeneic stem cell transplantation with
      supportive care.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of severe oral mucositis after stem cell transplantation</measure>
    <time_frame>5 weeks</time_frame>
    <description>from onset of severe oral mucositis till resolution of the mucositis or 28 days after stem cell transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe oral mucositis after stem cell transplantation</measure>
    <time_frame>5 weeks</time_frame>
    <description>from onset of severe oral mucositis till resolution of the mucositis or 28 days after stem cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average VAS score during severe oral mucositis</measure>
    <time_frame>5 weeks</time_frame>
    <description>from onset of severe oral mucositis till resolution of the mucositis or 28 days after stem cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of opioid drugs during severe oral mucositis</measure>
    <time_frame>5 weeks</time_frame>
    <description>from onset of severe oral mucositis till resolution of the mucositis or 28 days after stem cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of opioid drugs</measure>
    <time_frame>5 weeks</time_frame>
    <description>from onset of severe oral mucositis till resolution of the mucositis or 28 days after stem cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of palifermin during stem cell transplantation</measure>
    <time_frame>5 weeks</time_frame>
    <description>from admission for stem cell transplantation to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during transplant period</measure>
    <time_frame>5 weeks</time_frame>
    <description>1 week before stem cell infusion to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <arm_group_label>Palifermin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adequate organ function

          -  patients who will receive autologous stem cell transplantation

          -  patients who will receive allogeneic stem cell transplantation using myeloablative
             conditioning regimen

        Exclusion Criteria:

          -  presence of concomitant malignancy

          -  presence of active infection or oral mucositis prior to stem cell transplantation

          -  any conditions where the severity of oral mucositis cannot be evaluated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Ki-Seong Eom, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Palifermin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

